The long-awaited final report of the UK Review on Antimicrobial Resistance (AMR), commissioned by the British Government, in collaboration with the Wellcome Trust and led by economist Lord O’Neill, was released on 19 May 2016. It calls for global action at G20 and UN level, as well as for the pooling of international funds to tackle drug-resistant infections, thereby stressing the cross-border dimension of the threat. EPHA firmly believes that the European Union can and must set the ball rolling by devising a full public health policy approach to AMR that can be replicated in other parts of the world.
By Sascha Marschang, Policy Manager for Health Systems, EPHA
The long-awaited final report of the UK Review on Antimicrobial Resistance (AMR), commissioned by the British Government, in collaboration with the Wellcome Trust and led by economist Lord O’Neill, was released on 19 May 2016. It calls for global action at G20 and UN level, as well as for the pooling of international funds to tackle drug-resistant infections, thereby stressing the cross-border dimension of the threat. EPHA firmly believes that the European Union can and must set the ball rolling by devising a full public health policy approach to AMR that can be replicated in other parts of the world.
The final report of the UK Review on Antimicrobial Resistance pulls together the main recommendations of the previous eight thematic papers produced by the Review team. The report is significant because it puts a price tag on AMR and argues that the cost of global action on AMR represents but a tiny fraction of the cost of inaction, which might well amount to a shocking 10 million deaths annually and a cumulative loss of 100 trillion USD of economic output.
Fighting superbugs, now and everywhere
The report’s recommendations – warmly welcomed by EPHA – cover all aspects of the One Health approach to AMR while also addressing the need for boosting the infectious disease workforce and the pooling of international funds to address market failures and stimulate R&D of antimicrobials, alternatives and related products, including diagnostics, and are summarized in the following 10-point plan:
- A massive global awareness campaign
- Improve hygiene and prevent the spread of infections
- Reduce unnecessary use of antimicrobials in agriculture and their dissemination into the environment
- Improve global surveillance of drug resistance in humans and animals
- Promote new, rapid diagnostics to cut unnecessary use of antibiotics
- Promote the development and use of vaccines and alternatives
- Improve the numbers, pay and recognition of people working in infectious diseases
- Establish a Global Innovation Fund for early-stage and non-commercial research
- Better incentives to promote investment in new drugs and improving existing ones
- Build a global coalition for real action – via the G20 and the UN
EPHA is pleased to see that the report echoes the discussions of its December 2015 conference, acknowledging the importance of the environmental dimension of AMR. It proposes the establishment of ‘evidence-based, enforceable targets for maximum levels of antimicrobial active pharmaceutical ingredient (API) discharge’ during the production process of pharmaceutical products, coupled with improved waste processing facilities and monitoring of API emissions along the supply chain.
In human health, the uptake and use of rapid point-of-care diagnostics in primary and secondary care, supported by incentives (in high-income countries), could make a huge difference by preserving the effectiveness of existing drugs and revolutionising the way antibiotics are prescribed: this is currently still based on assessing patients’ symptoms and has not advanced into the digital age. Moreover, raising awareness globally and clamping down on over-the-counter sales are proposed to reduce consumption and correct misconceptions. For health institutions, there is a call to step up infection control and hygiene, in particular through improvements in hand washing.
In agriculture, EPHA welcomes the confirmation that far too many antibiotics are used in livestock production for purposes other than treating sick animals, e.g. to prevent infections or promote growth, and that excess use in animals also poses a threat to human health. The report thus calls for 10-year targets to reduce unnecessary use of antibiotics in agriculture, restrictions and bans of highly critical antibiotics, and mandatory transparency requirements (e.g. labelling) for food producers and retailers to ensure informed consumer decisions.
Regarding the broken innovation model for antimicrobials, the report proposes a several measures including better incentives to promote investment for new drugs and improve existing ones (e.g. market entry rewards, de-linkage models); as well as a global innovation fund for early-stage and non-commercial research which could link up already existing initiatives including also the IMI and the JPIAMR operating at EU level.
What role for Europe?
While stressing the merits of global surveillance and resource-sharing, the report does not propose a specific role for the EU in taking action on AMR. Regarding this, EPHA believes that the upcoming Council Conclusions of the Dutch Presidency can positively influence the revision of the European Commission’s Action Plan on AMR, and stimulate the Member States to formulate and/or revise ambitious National Action Plans that include SMART targets adapted to their specific national – and regional – situation. This in turn can set an example for the rest of the world given that coordinated global action is likely to take years, despite the WHO Global Action Plan provisions.
If Europe wishes to realise its ambition of being a global front-runner in the fight against AMR, then it must rise to the challenge and ensure that public health friendly good practices, targets and legislation are not only discussed and disseminated as part of a proposed One Health-AMR Network but are also taken up across the EU so that no country or region falls behind due to lack of knowledge, health system capacity or budgetary constraints. Drug-resistant infections are cross-border by nature and hence they cannot be defeated by countries working in isolation. The appetite for EU-level coordination generally may be low, but solidarity must reign over sovereignty when it comes to health threats that affect all people living in Europe.
